The PFA-100® cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations

References

• McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Factor VIII levels and blood group antigens. Thromb Haemost 1983; 50: 757
   PubMedGoogle Scholar
• Mohanty D, Ghosh K, Marwaha N, Kaur S, Chauhan AP, Das KC. Major blood group antigens–a determinant of factor VIII levels in blood?. Thromb Haemost 1984; 51: 414
   PubMedGoogle Scholar
• Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, Mateo J, Madoz P, Stone W, Blangero J, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000; 20: 2024–2028
   PubMed Web of Science ®Google Scholar
• Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N, Matsui T, Titani K, Katayama M, Yamamoto F, Yoshioka A. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 1995; 68: 236–240
   PubMed Web of Science ®Google Scholar
• Northfield TC. Factors predisposing to recurrent haemorrhage after acute gastrointestinal bleeding. Br Med J 1971; 1: 26–28
   PubMed Web of Science ®Google Scholar
• Kerr CB, Preston AE, Barr A, Biggs R. Inheritance of factor 8. Thromb Diath Haemorrh (suppl) 1965; 17: 173–179
   PubMedGoogle Scholar
• Kerr CB, Preston AE, Barr A, Biggs R. Further studies on the inheritance of factor 8. Br J Haematol 1966; 12: 212–233
   PubMedGoogle Scholar
• Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227–231
   PubMed Web of Science ®Google Scholar
• EPIC Study Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956–961
   PubMedGoogle Scholar
• PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436–443
   PubMed Web of Science ®Google Scholar
• IMPACT-II Study Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet 1997; 349: 1422–1428
   PubMedGoogle Scholar
• PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N Engl J Med 1998; 338: 1488–1497
   PubMed Web of Science ®Google Scholar
• PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators. N Engl J Med 1998; 338: 1498–1505
   PubMed Web of Science ®Google Scholar
• EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998; 352: 87–92
   PubMed Web of Science ®Google Scholar
• CAPTURE Study Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429–1435
   PubMedGoogle Scholar
• RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE investigators. Randomized efficacy study of tirofiban for outcomes and restenosis. Circulation 1997; 96: 1445–1453
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost 2001; 85: 369–370
   PubMed Web of Science ®Google Scholar
• Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001; 41: 56–60
   PubMed Web of Science ®Google Scholar
• Steinhubl SR. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study. J Thromb Thrombolysis 2000; 9: 199–205
   PubMedGoogle Scholar
• European Medicines Agency. Integrilin. Summary of Product Characteristics. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Integrilin/H-230-PI-en.pdf [Accessed 28 July 2009].
   Google Scholar
• Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26: 1665–1671
   PubMed Web of Science ®Google Scholar
• Tcheng JE. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. Am J Cardiol 1999; 83: E7–11
   Google Scholar
• Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000; 139: S38–45
   PubMed Web of Science ®Google Scholar
• Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995; 130: 877–892
   PubMed Web of Science ®Google Scholar